Citation

Altintoprak AE, Erol A, Koturoǧlu G, Gönül AS. Klin. Psikofarmakol. Bül. 2005; 15(4): 182-186.

Copyright

(Copyright © 2005, Kadıköy Hachette Yayıncılık)

DOI

unavailable

PMID

unavailable

Abstract

Clinical reports indicate that atypical antipsychotics are associated with a lower incidence of adverse events such as dose-related increases in prolactin concentrations than conventional antipsychotics. It has been shown that olanzapine causes less extrapyramidal movement disorder, hyperprolactinemia and sexual disfunction. Clinicians are confronted with challenging situations when working with women who are pregnant and have a co-existing mental illness. It is well known that potential consequences of an untreated psychotic episode may be severe and may lead to the mother attempting suicide and/or infanticide. For these reasons, clinicians need to help mothers weigh both fetal and neonatal risks of exposure to drugs against the potential risk they and their infant may incur if the psychiatric illness is not treated. Although data regarding conventional antipsychotics and pregnancy are available, reports about the course of pregnancy in women treated with atypical agents are insufficient. Understanding the risk of prenatal antipsychotic exposure can be of benefit in selecting therapies. Here we present a woman who was treated with olanzapine before and during her pregnancy and her baby.

Language: tr

Keywords

adult; human; female; Pregnancy; case report; infanticide; psychosis; suicide attempt; Olanzapine; pregnancy; article; mental disease; sexual dysfunction; olanzapine; extrapyramidal syndrome; hyperprolactinemia; atypical antipsychotic agent; female fertility; prenatal drug exposure; Atypical antipsychotics; Teratogenity